Clinical trials: Paragangliomas
Neuroendocrine Tumor, Neuroblastoma
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and…
- Conditions
- Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT05069220
- Testing
- 18F-MFBG, 68Ga-Dotatate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT03008369
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Paraganglioma
Exendin PET/CT for Imaging of Paragangliomas
Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets.
- Trial name
- ENTRAP (NCT05418907)
- Testing
- 68Ga-NODAGA-exendin-4 PET/CT
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
This study is a phase 2, open, single-site trial. The primary objective of this study is to prospectively evaluate the safety and efficacy in participants treated with Lu-177 DOTATATE (Lutathera) in unresectable or metastatic…
- Conditions
- Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma, Those Requiring Repeat Peptide Receptor Radionuclide Therapy
- Trial name
- NCT06121271
- Testing
- Lu-177 DOTATATE (Lutathera®)
- Volunteers
- 110 people
- Sponsor
- University College, London
Paraganglioma
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green
This study is exploring whether it's possible to detect paragangliomas (a rare type of tumor) during minimally invasive surgery by using a technique called near-infrared fluorescence imaging, guided by a substance called…
- Trial name
- NCT06155734
- Testing
- Fluorescence guided identification using indocyanine green
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Leiden University Medical Center
Pheochromocytoma, Paraganglioma
Preoperative Alpha Blockade for Pheochromocytoma
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and…
- Trial name
- NCT03176693
- Testing
- Phenoxybenzamine, Doxazosin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
Head and Neck Paraganglioma
Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey
The aim of the study is to examine the head and neck paraganglioma cases treated in Pamukkale University hospital between 2007-2023 and improve our understanding of these cases and contribute to the knowledge surrounding head and…
- Trial name
- NCT05942482
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Pamukkale University
Pheochromocytoma, Metastatic, Ultrasonography
Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of…
- Conditions
- Pheochromocytoma, Metastatic, Ultrasonography, Paraganglioma, Malignant, Pheochromocytoma Malignant
- Trial name
- NCT06015061
- Testing
- Contrast-enhanced ultrasound(CEUS)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Currently there is no known effective treatment for patients with advanced stage neuroblastoma who have relapsed or not responded to standard therapy.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01838187
- Testing
- I-131 MIBG, Vorinostat
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Pheochromocytoma, Paraganglioma
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Pheochromocytomas and paragangliomas (PPGLs) are chromaffin cells-derived tomours that originate from the adrenal medulla (80~85%) and the extra-adrenal sympathetic paraganglia in thorax, abdomen and pelvis (15~20%) or…
- Trial name
- NCT05948137
- Testing
- F-18 FDOPA PET/CT
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Asan Medical Center
Pheochromocytoma, Metastatic, Pheochromocytoma Malignant
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase…
- Conditions
- Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant
- Trial name
- NCT05885399
- Testing
- Penpulimab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05883085
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Metastatic, Paraganglioma, Malignant
The Efficacy and Safety of Temozolomide in Patients With MPPGL
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent.
- Conditions
- Pheochromocytoma, Metastatic, Paraganglioma, Malignant, Pheochromocytoma Malignant
- Trial name
- MPPGL (NCT05858177)
- Testing
- Temozolomide capsule
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking Union Medical College Hospital
Paraganglioma, Pheochromocytoma
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late.
- Conditions
- Paraganglioma, Pheochromocytoma, Genetic Predisposition to Disease, Pathology
- Trial name
- PPGL-Pred (NCT04788927)
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Paragangliomas, Pheochromocytomas
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
18F-FDOPA PET-CT is currently the gold standard in the evaluation of Pheochromocytomas and Paragangliomas (PHEO - PGL) since these tumors can also decarboxylate amino acids such as dihydroxyphenylalanine (DOPA).
- Trial name
- DOTATATE (NCT02186678)
- Testing
- PET-CT
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neuroendocrine Tumors
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
- Trial name
- NCT00442533
- Testing
- Indium-111 pentetreotide
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Radio Isotope Therapy of America
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
PGL
Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection
This observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(PPGL) resection. It mainly answers the following two main questions: 1.
- Trial name
- MI-PPGL (NCT05752773)
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Peking Union Medical College Hospital
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.